Coronavirus (COVID-19)
Learn more
March 13, 2013
Location: The Hospital of Central Connecticut
A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat for Higher-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.